Toxicology News and Research

Latest Toxicology News and Research

NGOs, IAOMT urge to ban mercury-containing products, including dental amalgam

Mercury, the main ingredient in "silver" or amalgam fillings, will be the subject of a United Nations conference to be held in Chiba, Japan on January 24-28. Members of various non-governmental organizations, as well as dentists and scientists from groups such as the International Academy of Oral Medicine and Toxicology, will be attending and urging a ban on products containing mercury, including dental amalgam.

21 Jan 2011

New study provides insight into developing therapeutics for airway disease

Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease.

19 Jan 2011

Smoking harms DNA within minutes: Study

According to the latest research in the US, smoking tobacco damages the body in minutes rather than years. The study was published in the Chemical Research in Toxicology revealed that the chemicals which cause cancer form rapidly after smoking.

16 Jan 2011

Simulations Plus first quarter consolidated revenues increase 15.4% to record $2.811M

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its first quarter of fiscal year 2011 ended November 30, 2010 (1QFY11).

14 Jan 2011

ShangPharma opens new multi-purpose pharma development and cGMP manufacturing facility in Fengxian

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced commencement of operations on the initial phase of production at the Company's Fengxian facility. This new multi-purpose pharmaceutical development and cGMP manufacturing facility is located in Fengxian in the suburbs of Shanghai, China.

14 Jan 2011

SRI International receives $17.4 million grant to boost treatments for cardiovascular, lung, blood diseases

SRI International, an independent nonprofit research and development organization, announced today that it has been awarded two preclinical services contracts totaling $17.4 million by the National Heart, Lung, and Blood Institute, one of the National Institutes of Health.

13 Jan 2011

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

Celator, Cephalon extend cancer research agreement

Celator Pharmaceuticals today announced that it has agreed with Cephalon, Inc. to extend an existing research agreement into the next phase of development. The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.

10 Jan 2011

USDTL launches two new tests for monitoring long-term alcohol exposure using fingernail, hair specimens

United States Drug Testing Laboratories launched two new tests for monitoring long-term alcohol exposure on Friday. Using fingernail and hair specimens, the new assay is the first and only test to report a donor's alcohol exposure for the past 90 days reliably.

10 Jan 2011

Entelos receives U.S. Patent for Predictive Toxicology for Biological Systems

Entelos, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,853,406 entitled "Predictive Toxicology for Biological Systems" to the Company.

9 Jan 2011

Metabolon announces publication of 'Metabolomic Distinction and Insights into the Pathogenesis of Human Primary Dilated Cardiomyopathy'

Metabolon, the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Metabolomic Distinction and Insights into the Pathogenesis of Human Primary Dilated Cardiomyopathy", in the European Journal of Clinical Investigation.

6 Jan 2011

Studded tires can cause damage to public health and pavement

Scientists are reporting new evidence on how studded tires - wintertime fixtures in some areas but banned in others for causing damage to pavement - may also damage the health of motorists and people living near highways.

6 Jan 2011

Researchers create model that predicts drug effects on fetal development

When pregnant women need medications, there is often concern about possible effects on the fetus. Although some drugs are clearly recognized to cause birth defects, and others are generally recognized as safe, surprisingly little is known about most drugs' level of risk. Researchers in the Children's Hospital Boston Informatics Program have created a preclinical model for predicting a drug's teratogenicity based on characterizing the genes that it targets.

5 Jan 2011

PanOptica completes $30 million Series A financing

PanOptica, Inc., a private biopharmaceutical company focused on licensing and developing innovative ophthalmology therapies, today announced that it has raised $30 million in a Series A financing. This round was led by SV Life Sciences and Third Rock Ventures.

4 Jan 2011

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.

28 Dec 2010

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010

Tap water cancer chemical detected

A new analysis has revealed a potential carcinogen in the tap water of 31 U.S. cities and experts are looking for ways to reduce exposure of the communities. The chemical called hexavalent chromium, got public attention in the 2000 film “Erin Brockovich” and has been found to cause cancer in laboratory animals by the National Toxicology Program, part of the National Institutes of Health.

21 Dec 2010

Study reveals novel role of adenosine signaling in sickle cell disease

Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Novel Role of Adenosine Signaling in Sickle Cell Disease", in Nature Medicine. Application of non-targeted biochemical profiling (metabolomics) to a mouse model of sickle cell disease (SCD) revealed a detrimental role of adenosine signaling in SCD and suggested novel therapeutic targets. The study was carried out in collaboration with The University of Texas Health Science Center at Houston.

21 Dec 2010

VistaGen reports successful completion of AV-101 Phase 1 safety study for neuropathic pain

VistaGen Therapeutics, Inc., a stem cell technology company focused on drug discovery and development, today announced the successful completion of its initial Phase 1 safety study of AV-101, the Company's novel orally available prodrug candidate for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S.

20 Dec 2010

InterMune's MAA for Esbriet receives positive CHMP opinion

InterMune, Inc. today announced additions to its senior leadership team to prepare for the commercialization of Esbriet™ (pirfenidone) in Europe. InterMune's Marketing Authorization Application (MAA) for Esbriet received a positive CHMP opinion that is now awaiting ratification by the European Commission.

20 Dec 2010

Toxicology News and Research

Latest Toxicology News and Research

NGOs, IAOMT urge to ban mercury-containing products, including dental amalgam

New study provides insight into developing therapeutics for airway disease

Smoking harms DNA within minutes: Study

Simulations Plus first quarter consolidated revenues increase 15.4% to record $2.811M

ShangPharma opens new multi-purpose pharma development and cGMP manufacturing facility in Fengxian

SRI International receives $17.4 million grant to boost treatments for cardiovascular, lung, blood diseases

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Celator, Cephalon extend cancer research agreement

USDTL launches two new tests for monitoring long-term alcohol exposure using fingernail, hair specimens

Entelos receives U.S. Patent for Predictive Toxicology for Biological Systems

Metabolon announces publication of 'Metabolomic Distinction and Insights into the Pathogenesis of Human Primary Dilated Cardiomyopathy'

Studded tires can cause damage to public health and pavement

Researchers create model that predicts drug effects on fetal development

PanOptica completes $30 million Series A financing

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Tap water cancer chemical detected

Study reveals novel role of adenosine signaling in sickle cell disease

VistaGen reports successful completion of AV-101 Phase 1 safety study for neuropathic pain

InterMune's MAA for Esbriet receives positive CHMP opinion

Forensics and toxicology - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Toxicology News and Research

Latest Toxicology News and Research

Forensics and toxicology - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in